TSHA
Taysha Gene Therapies, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.60
+0.54%Aug 12, 2026, 01:37 UTC
Taysha Gene Therapies, Inc. held its Q2 2026 earnings call on August 11, 2026.
Source:Aug 12, 2026, 01:04 UTC
Taysha Gene Therapies completed dosing in its REVEAL pivotal trial and ASPIRE trial for TSHA-102, its gene therapy candidate for Rett syndrome, and is preparing for a potential biologics license application submission.
Source:Jun 25, 2026, 00:00 UTC
Taysha Gene Therapies signed an underwriting agreement for an underwritten public offering of 32,500,001 common shares and 833,333 pre-funded warrants, with estimated net proceeds of approximately $187.4 million.
Source:Jun 5, 2026, 12:01 UTC
Taysha Gene Therapies granted restricted stock units and stock options to four new employees as an inducement for their employment.
Source: